Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Johns Hopkins Hospital, Baltimore, Maryland Mayo Clinic, Rochester, Minnesota Vanderbilt Bill Wilkerson Center, Nashville, Tennessee University of Texas Southwestern, Dallas, Texas